RAB Diagnostics

📍 Oslo, Norway🗓 Founded 2023👥 8 employees💰 Last funded Jan 2026
Biotechnology Research🌐 rabdiagnostics.com
Website LinkedIn
Rab Diagnostics specializes in biomarker development for oncology-focused Antibody-Drug Conjugates (ADCs). Through our proprietary RabCANCER platform and deep expertise in intracellular drug trafficking, we provide high-quality, mechanism-driven insights to accelerate drug development and enable precision medicine. We bridge the gap between preclinical discoveries and clinical implementation by developing robust research tools and diagnostic kits, translating insights into clinical solutions. Based on world class science at Oslo University Hospital and headquartered in Oslo, Norway, collaborative partnerships and scientific rigor are in our DNA. We support biopharmaceutical companies in delivering precise, effective cancer therapies to patients worldwide.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Norway
1
Frequently asked questions
Who invested in RAB Diagnostics?
RAB Diagnostics has 1 investors on record on gritt.io, 1 mid-stage.
When did RAB Diagnostics last raise funding?
The most recent investment in RAB Diagnostics recorded on gritt.io was in January 2026.
When was RAB Diagnostics founded?
RAB Diagnostics was founded in 2023.
What industry is RAB Diagnostics in?
RAB Diagnostics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is RAB Diagnostics based?
RAB Diagnostics is headquartered in Oslo, Norway.